MY145329A - Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423) - Google Patents

Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423)

Info

Publication number
MY145329A
MY145329A MYPI20051274A MYPI20051274A MY145329A MY 145329 A MY145329 A MY 145329A MY PI20051274 A MYPI20051274 A MY PI20051274A MY PI20051274 A MYPI20051274 A MY PI20051274A MY 145329 A MY145329 A MY 145329A
Authority
MY
Malaysia
Prior art keywords
pharmaceutical dosage
phthalimidoethoxy
alanyl
acetyl
glutamic acid
Prior art date
Application number
MYPI20051274A
Other languages
English (en)
Inventor
Marija Bogataj
Janez Kerc
Rok Dreu
Fumio Yoneda
Shizuko Muraoka
Ales Mrhar
Anton Lavric
Manica Cerne
Doris Tibaut
Anton Stalc
Uros Urleb
Tatjana Mateovic
Greta Cof
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Publication of MY145329A publication Critical patent/MY145329A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MYPI20051274A 2004-03-26 2005-03-24 Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423) MY145329A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SI200400094 2004-03-26

Publications (1)

Publication Number Publication Date
MY145329A true MY145329A (en) 2012-01-31

Family

ID=34964906

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20051274A MY145329A (en) 2004-03-26 2005-03-24 Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423)

Country Status (15)

Country Link
US (1) US20100183714A1 (https=)
EP (1) EP1734933B1 (https=)
JP (1) JP2007530492A (https=)
CN (1) CN1956707B (https=)
AR (1) AR048342A1 (https=)
AT (1) ATE468846T1 (https=)
AU (1) AU2005226927B2 (https=)
BR (1) BRPI0509271A (https=)
CA (1) CA2559685A1 (https=)
DE (1) DE602005021475D1 (https=)
MY (1) MY145329A (https=)
PE (1) PE20051163A1 (https=)
RU (1) RU2375047C2 (https=)
TW (1) TW200600121A (https=)
WO (1) WO2005092295A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273376B2 (en) 2006-11-17 2012-09-25 Da Volterra Colonic delivery of metallo-dependent enzymes
CN101795675A (zh) * 2006-11-17 2010-08-04 达沃尔泰拉公司 使用具有Eudragit包衣的Zn/果胶珠粒进行的结肠递送
WO2009037264A2 (en) * 2007-09-17 2009-03-26 Da Volterra Colonic delivery of antimicrobial agents
ES2627745T3 (es) * 2008-11-13 2017-07-31 Nogra Pharma Limited Composiciones antisentido, y procedimientos de fabricación y uso de las mismas
EP3915552A1 (en) * 2015-06-01 2021-12-01 Xeno Biosciences Inc. Compositions for use in modulating the gut microbiota and managing weight
BR112018077032A2 (pt) * 2016-06-23 2019-04-02 Nutrivert Llc método para aprimorar o crescimento ou a conversão alimentar em um animal, uso de pgn, mdp ou um análogo de mdp na preparação de um medicamento e pgn, mdp ou um análogo de mdp
WO2018085935A1 (en) * 2016-11-09 2018-05-17 Engene, Inc. Intestinal expression of programmed death ligand 1
BR112019012071A2 (pt) * 2016-12-14 2019-11-12 Progenity Inc tratamento de uma doença do trato gastrointestinal com um inibidor de integrina
EP3554485B9 (en) * 2016-12-14 2023-09-27 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
EP3554342B1 (en) * 2016-12-14 2024-07-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
CN108968074B (zh) * 2018-06-06 2021-09-28 福建省农业科学院农业工程技术研究所 一种结肠靶向递送的银耳糖醛酸多糖-芙蓉李花青素复合物及其制备方法
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법
ES3014076T3 (en) 2020-03-26 2025-04-16 Nutrivert Inc Lipophilic enantiomers of desacetylglucosamine muramyl dipeptide with anti-inflammatory and growth promoting activity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2113221C1 (ru) * 1990-05-04 1998-06-20 Ииссум Рисерч Дивелопмент Компани оф дзе Хебрю Юниверсити оф Иеруcалим Фармацевтическая форма для введения лекарственного средства в ободочную кишку, способ введения лекарственного препарата и способ получения матриц для такой формы
JP2773959B2 (ja) * 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
YU183090A (sh) * 1990-09-27 1992-12-21 Lek Novi n-acildipeptidi, postopki za njihovo pripravo in farmacevtski pripravki, kojih vsebujejo
DE19732903A1 (de) * 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems

Also Published As

Publication number Publication date
ATE468846T1 (de) 2010-06-15
PE20051163A1 (es) 2006-02-21
EP1734933A1 (en) 2006-12-27
US20100183714A1 (en) 2010-07-22
RU2006137660A (ru) 2008-05-10
CA2559685A1 (en) 2005-10-06
EP1734933B1 (en) 2010-05-26
AU2005226927A1 (en) 2005-10-06
CN1956707A (zh) 2007-05-02
JP2007530492A (ja) 2007-11-01
BRPI0509271A (pt) 2007-09-04
AR048342A1 (es) 2006-04-19
RU2375047C2 (ru) 2009-12-10
DE602005021475D1 (de) 2010-07-08
AU2005226927B2 (en) 2010-09-23
CN1956707B (zh) 2010-12-29
WO2005092295A1 (en) 2005-10-06
TW200600121A (en) 2006-01-01

Similar Documents

Publication Publication Date Title
CY2025003I2 (el) Λιποσωματα για τη χορηγηση φαρμακων συνθεσεις για τη θεραπευτικη αγωγη γαστρεντερικων διαταραχων
FR15C0009I2 (fr) Compositions de gel phospholipide destinees a l'administration medicamenteuse et des methodes de traitement utilisant celles-ci
WO2005094374A3 (en) Hydrazide-containing cftr inhibitor compounds and uses thereof
EP1848270A4 (en) TRANSMUCOSAL ADMINISTRATION OF MEDICINAL PREPARATIONS FOR THE TREATMENT AND PREVENTION OF DISEASES IN ANIMALS
DE60325379D1 (de) Zusammensetzung enthaltend 6-Ä3-(1-adamantyl)-4-methoxyphenylÜ-2-naphthanoesäure zur Behandlung dermatologischer Erkrankungen
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
MX395136B (es) Composiciones farmaceuticas y metodos de administracion relacionados.
MY145329A (en) Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423)
NO20075660L (no) Blanding for behandling av inflammatoriske sykdommer
EP1848541A4 (en) METHOD AND DEVICE FOR THE OPHTHALMIC ADMINISTRATION OF PHARMACEUTICAL ACTIVE SUBSTANCES
WO2008021088A3 (en) Salicylanilides enhance oral delivery of therapeutic peptides
WO2011151722A3 (en) Methods and compositions for oral pharmaceutical therapy
TW200635618A (en) Solid dosage form comprising proton pump inhibitor and suspension made thereof
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
WO2007140005A3 (en) Oxazolyl piperidine modulators of fatty acid amide hydrolase
WO2007061862A3 (en) 2-keto-oxazoles as modulators of fatty acid amide hydrolase
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
EA200800147A1 (ru) Способ получения олмесартан медоксомила
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
ATE369355T1 (de) Pyrimidinamid derivate und deren verwendung
ATE453646T1 (de) 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
UA96794C2 (ru) Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen